Rapid responders to frovatriptan in acute migraine treatment: Results from a long-term, open-label study

Egilius L.H. Spierings, Charlotte Keywood, Jeffrey Baggish, Harvey J. Blumenthal, Roger K. Cady, David H. Cook, Seymour Diamond, Keith R. Edwards, David L. Friedgood, Ronald C. Gove, Daniel B. Hier, Robert G. Kaniecki, David Kudrow, Theodore E. Lefton, H. Edward Logue, William E. McIntosh, W. Walter Menninger, Teri Perse, John A.H. Porter, Alan M. RapoportRobert E. Ryan, Sara E. Sacco, Carl H. Sadowsky, Joel R. Saper, Frederick W. Schaerf, Jay A. Schecter, Elliot A. Schulman, Egilius L.H. Spierings, Stephen D. Silberstein, Stuart R. Stark, Gus Stratton, Stewart J. Tepper, Jerry Tindel

Research output: Contribution to journalArticlepeer-review

8 Scopus citations


Background. The chronic nature of migraine and the reliance on acute treatment constitute the basis of the present long-term, open-label study. Objectives. First, assessment of the tolerability and safety of frovatriptan, 2.5-7.5 mg taken orally over 24 hours, for the acute treatment of migraine, repeatedly over a 12-month period. Second, assessment of the efficacy and tolerability of a second, double-blind dose of 2.5-mg frovatriptan, compared with placebo, for nonresponse at 2 hours after treatment of moderate or severe headache with 2.5-mg frovatriptan. Results. With regard to the first attack treated, 173 (36%) of the 486 subjects in the study did not take a second dose at 2 hours for nonresponse. At 2 hours and 4 hours, these "rapid responders" experienced a decrease in headache intensity from moderate or severe to mild or no pain in 84% and 98%, respectively ("headache response"). Six percent of them experienced recurrence of moderate or severe headache within 24 hours following a response at 4 hours and 12% took rescue medication. The response, measured in terms of median time to "complete migraine relief," was maintained over 30 subsequent migraine attacks, treated from attack 2 onwards over the course of 12 months. Conclusion. Frovatriptan provides a remarkably fast and high headache response in a subgroup of more than one-third of migraineurs, with a very low 24-hour headache recurrence and low rescue medication intake.

Original languageEnglish (US)
Pages (from-to)633-638
Number of pages6
JournalPain Medicine
Issue number4
StatePublished - 2009
Externally publishedYes


  • Complete migraine relief
  • Frovatriptan
  • Headache freedom
  • Headache recurrence
  • Headache response
  • Migraine treatment
  • Rapid responders

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Rapid responders to frovatriptan in acute migraine treatment: Results from a long-term, open-label study'. Together they form a unique fingerprint.

Cite this